Importantly, the stimulatory effects of LINC00173.v1 overexpression on the proliferation and migration of vascular endothelial cells in vitro and the tumorigenesis of lung cancer cells in vivo were differentially abrogated by recombinant VEGF monoclonal antibody bevacizumab, agomir-511-5p and mutant LINC00173.v1. This evidence concerns the gene VEGFA and lung carcinoma.